吉林敖东：2025年全年净利润同比预增46.00%—60.00%

Core Viewpoint - Jilin Aodong forecasts a significant increase in net profit for 2025, projecting a year-on-year growth of 46.00% to 60.00% [1] Financial Performance - The company expects net profit attributable to shareholders to be between 226,503.39 million and 248,222.90 million yuan for 2025 [1] - The projected net profit excluding non-recurring gains and losses is estimated to be between 206,934.46 million and 228,653.97 million yuan, reflecting a year-on-year increase of 31.56% to 45.37% [1] - The impact of non-recurring gains and losses on net profit is expected to be approximately 19,568.93 million yuan, compared to -2,151.12 million yuan in the same period of 2024 [1] Strategic Focus - The company is focusing on value management and enhancing operational quality within its pharmaceutical core business [1] - It is implementing a sales strategy centered on "large product groups and multiple product groups" while pursuing a dual-driven growth model of "pharmaceutical health + financial capital" [1] - The company is progressing according to its valuation enhancement plan established at the beginning of the year, contributing to substantial performance growth [1]